Telix Submits European Marketing Authorisation Application for Prostate Cancer Imaging Product
2020-05-01 · Telix Pharmaceuticals (Innovations) Pty Limited · original telixpharma.com ↗
Telix Submits European Marketing Authorisation Application for Prostate Cancer Imaging Product Melbourne (Australia) and Liège (Belgium) – 1st May 2020. Telix has submitted a marketing authorisation application (MAA) in Europe for TLX591-CDx Telix Pharmaceuticals Limited is pleased to announce that it has submitted a marketing authorisation application (MAA) in Europe for TLX591-CDx (68Ga-PSMA-11 Injection) for the imaging of prostate cancer with Positron Emission Tomography (PET). The submission has been made to the Danish Medicines Agency (DKMA) in its capacity as a reference Competent Authority of a European member state. The DKMA will coordinate and lead the evaluation of Telix’s MAA for TLX591-CDx on behalf of Denmark as well as a selection of European countries, nominated by Telix. These countries reflect the major European markets for Telix’s prostate cancer imaging product. To read the full media release please click here.
The release as fetched from its publisher. telixpharma.com ↗